Robert W. Baird Lowers Humana (NYSE:HUM) Price Target to $205.00

Humana (NYSE:HUM) had its target price reduced by equities researchers at Robert W. Baird from $264.00 to $205.00 in a research note issued on Wednesday,MarketScreener reports. The firm presently has a “neutral” rating on the insurance provider’s stock. Robert W. Baird’s target price would indicate a potential upside of 2.16% from the stock’s current price.

Several other analysts have also recently weighed in on HUM. Raymond James Financial cut their price target on shares of Humana from $340.00 to $230.00 and set an “outperform” rating on the stock in a report on Friday, February 13th. Truist Financial lifted their price target on shares of Humana from $200.00 to $220.00 and gave the company a “hold” rating in a report on Monday. The Goldman Sachs Group cut their price target on shares of Humana from $215.00 to $158.00 and set a “sell” rating on the stock in a report on Friday, February 13th. Royal Bank Of Canada cut shares of Humana from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $322.00 to $189.00 in a report on Thursday, February 12th. Finally, Zacks Research upgraded shares of Humana from a “strong sell” rating to a “hold” rating in a report on Thursday, March 5th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Humana presently has an average rating of “Hold” and an average target price of $222.09.

Humana Stock Performance

NYSE:HUM opened at $200.66 on Wednesday. The stock has a market cap of $24.09 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 2.13 and a beta of 0.44. The firm’s fifty day simple moving average is $181.09 and its 200 day simple moving average is $231.32. Humana has a twelve month low of $163.11 and a twelve month high of $315.35. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, research analysts predict that Humana will post 16.47 EPS for the current year.

Insider Buying and Selling

In other news, insider Sanjay K. Shetty acquired 810 shares of the stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, with a total value of $150,020.10. Following the completion of the transaction, the insider owned 11,657 shares of the company’s stock, valued at $2,158,992.97. This represents a 7.47% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Hedge Funds Weigh In On Humana

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Montag A & Associates Inc. lifted its position in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares during the period. CoreCap Advisors LLC lifted its position in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after buying an additional 37 shares during the period. Fideuram Asset Management Ireland dac purchased a new position in shares of Humana in the 4th quarter worth about $27,000. Reflection Asset Management purchased a new position in shares of Humana in the 4th quarter worth about $29,000. Finally, Rosenberg Matthew Hamilton raised its position in shares of Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Board-approved quarterly dividend ($0.885/share) reinforces cash return to shareholders and supports yield-focused demand; dividend payable July 31 with record date June 26. Humana Board Declares Payment of Quarterly Dividend to Stockholders
• Positive Sentiment: Truist raised its price target to $220, which signals some analyst conviction in Humana’s recovery potential and can provide buying interest from momentum/target-driven investors. Truist Financial Increases Humana (NYSE:HUM) Price Target to $220.00
• Positive Sentiment: Jim Cramer discussed Humana’s sizable business on TV — positive media coverage can boost retail attention and short-term demand. Jim Cramer Discusses Big Humana (HUM) Business
• Positive Sentiment: Humana-backed research (telephone training for COPD patients) highlights clinical outcomes and value-based care initiatives that support long-term Medicare Advantage positioning. This is favorable for investor sentiment around durable growth drivers. On the Line for Lung Health: Telephone Training Helps COPD Patients Perfect Inhaler Use
• Neutral Sentiment: Robert W. Baird trimmed its price target to $205 from $264 but kept a “neutral” rating — reduces upside implied by some analysts but is less severe than an outright sell call. Baird adjusts price target on Humana to $205 from $264; maintains neutral rating
• Negative Sentiment: Zacks Research downgraded HUM to “Strong Sell” and nudged down Q1–Q3 2027 EPS estimates slightly — a headline downgrade can prompt short-term selling pressure and influence sentiment among institutional managers. Zacks Research downgrade coverage
• Negative Sentiment: Data breach impacting Humana customers across Texas and five other states introduces reputational risk, potential remediation costs and regulatory scrutiny — a material negative for near-term risk perception. Data breach hits Humana customers in Texas, five other states

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.